Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

Reboxetine is, overall, an ineffective and potentially harmful antidepressant and Published evidence is affected by publication bias, underlining the urgent need for mandatory publication of trial data.

Abstract

Reboxetine is, overall, an ineffective and potentially harmful antidepressant. Published evidence is affected by publication bias, underlining the urgent need for mandatory publication of trial data.